Table 1 Characteristics of participants included in the analyses
Characteristic | Cohort (n = 56) | Ischaemic stroke (n = 29) | Stroke mimic (n = 27) | p value |
|---|---|---|---|---|
Part 1: analysis including whole cohort | ||||
Age | 66.8 (58.8–74.7) | 66.8 (58.8–74.7) | 67.0 (59.7–74.9) | 0.768 |
BMI | 28.2 (25.3–31.2) [3] | 29.4 (25.7–33.2) | 27.7 (24.1–30.0) [3] | 0.110 |
Symptom duration* | 2.6 (1.2–4.7) [7] | 1.8 (1.2–4.4) [3] | 3.2 (1.7–4.8) [4] | 0.336 |
Male sex | 28 (50.0%) | 15 (51.7%) | 13 (48.1%) | 1.000 |
NIHSS score at presentation | NA | 2.0 (1.0–4.5) [7] | NA | NA |
Smoking history | ||||
Never smoked | 23 (41.1%) | 12 (41.4%) | 11 (40.7%) | 0.832 |
Ex-smoker | 23 (41.1%) | 11 (37.9%) | 12 (44.4%) | |
Current smoker | 10 (17.9%) | 6 (20.7%) | 4 (14.8%) | |
History of | ||||
Hypertension | 38 (67.9%) | 20 (69.0%) | 18 (66.7%) | 1.000 |
CHD | 20 (35.7%) | 12 (41.4%) | 8 (29.6%) | 0.412 |
TIA | 14 (25.0%) | 8 (27.6%) | 6 (22.2%) | 0.761 |
Stroke | 25 (44.6%) | 18 (62.1%) | 7 (25.9%) | 0.008 |
Diabetes | 10 (17.9%) | 6 (20.7%) | 4 (14.8%) | 0.731 |
Prescription for | ||||
Aspirin | 14 (25.0%) | 7 (24.1%) | 7 (25.9%) | 1.000 |
Other antiplatelet agents | 6 (10.7%) | 3 (10.3%) | 3 (11.1%) | 1.000 |
Calcium channel blockers | 9 (16.1%) | 4 (13.8%) | 5 (18.5%) | 0.725 |
Beta blockers | 13 (23.2%) | 6 (20.7%) | 7 (25.9%) | 0.756 |
ACE inhibitors | 9 (16.1%) | 6 (20.7%) | 3 (11.1%) | 0.472 |
Statins | 21 (37.5%) | 12 (41.4%) | 9 (33.3%) | 0.589 |
Characteristic | Cohort (n = 54) | Ischaemic stroke (n = 29) | Stroke mimic (n = 25) | p value |
|---|---|---|---|---|
Part 2: analysis excluding participants with metastatic disease | ||||
Age | 66.8 (58.5–74.8) | 66.8 (58.5–74.8) | 67.0 (59.6–75.2) | 0.835 |
BMI | 28.0 (25.2–31.3) [2] | 29.4 (25.7–33.2) | 27.7 (24.0–30.1) [2] | 0.098 |
Symptom duration (hours)* | 2.6 (1.3–4.7) [7] | 1.8 (1.2–4.4) [3] | 3.2 (1.8–4.7) [4] | 0.314 |
Male sex | 26 (48.1%) | 15 (51.7%) | 11 (44.0%) | 0.769 |
NIHSS score at presentation | NA | 2.0 (1.0–4.5) [7] | NA | NA |
Smoking history | ||||
Never smoked | 23 (42.6%) | 12 (41.4%) | 11 (44.0%) | 0.718 |
Ex-smoker | 22 (40.7%) | 11 (37.9%) | 11 (44.0%) | |
Current smoker | 9 (16.7%) | 6 (20.7%) | 3 (12.0%) | |
History of | ||||
Hypertension | 36 (66.7%) | 20 (69.0%) | 16 (64.0%) | 0.777 |
CHD | 20 (37.0%) | 12 (41.4%) | 8 (32.0%) | 0.576 |
TIA | 14 (25.9%) | 8 (27.6%) | 6 (24.0%) | 1.000 |
Stroke | 23 (42.6%) | 18 (62.1%) | 5 (20.0%) | 0.002 |
Diabetes | 10 (18.5%) | `6 (20.7%) | 4 (16.0%) | 0.736 |
Prescription for | ||||
Aspirin | 13 (24.1%) | 7 (24.1%) | 6 (24.0%) | 1.000 |
Other antiplatelet agents | 6 (11.1%) | 3 (10.3%) | 3 (12.0%) | 1.000 |
Calcium channel blockers | 9 (16.7%) | 4 (13.8%) | 5 (20.0%) | 0.718 |
Beta blockers | 13 (24.1%) | 6 (20.7%) | 7 (28.0%) | 0.751 |
ACE inhibitors | 9 (16.7%) | 6 (20.7%) | 3 (12.0%) | 0.480 |
Statins | 20 (37.0%) | 12 (41.4%) | 8 (32.0%) | 0.576 |